USE OF LH ADMINISTERED IN THE MIDDLE OR LATE FOLICULAR PHASE FOR THE TREATMENT OF ANOVULATORY WOMEN.

摘要

The use of LH and / or an analogue thereof biologically active in the production of a drug to induce paucifoliculogenesis or unifoliculogenesis in anovulatory women at a daily dose in the range of 100 to 1500 IU, where the medication should be administered starting the phase medium or late follicular.